Table 4.
Comparison of some clinical and laboratory data of TT allele carriers in the control and primary hypertension group
| Variables | TT controls | TT patients with PH | p |
|---|---|---|---|
| Number of pts (%) | 8 (9.6 %) | 13 (10.3 %) | ns |
| BMI (kg/m2) | 20.7 ± 3.7 | 25.6 ± 6.3 | 0.07 |
| BMI-SD | 0.62 ± 0.98 | 1.89 ± 2.05 | ns |
| cIMT (mm) | 0.41 (0.31–0.44) | 0.46 (0.37–0.57) | 0.04 |
| cIMT-SDS | 0.67 (−1.58 to 1.72) | 1.49 (−0.35 to 2.52) | 0.07 |
| hsCRP (mg/l) | 0.24 (0.15–0.71) | 0.41 (0.14–0.82) | ns |
| TTG/HDL | 1.8 (1.0–2.9) | 1.8 (0.8–2.9) | ns |
| Fasting insulin (mU/ml) | 12 (7.6–12) | 12.9 (6.7–30) | 0.1 |
| HOMA-IR | 2.42 (1.06–2.85) | 2.64 (1.38–6.23) | ns |
Data are presented as the mean ± SD, as the median with the range in parenthesis or as a number with the percentage in parenthesis, as appropriate
BMI body mass index, cIMT carotid intima-media thickness, hsCRP high-sensivity C-reactive protein, TTG/HDL total triglycerydes/ high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment for insulin resistance